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Abstract 
Purpose: To evaluate the antibacterial, enzyme-inhibitory and hemolytic activities of S-
alkylated/aralkylated 2-(1H-indol-3-ylmethyl)-1,3,4-oxadiazole-5-thiol derivatives. 
Methods: Antibacterial activities of the compounds were evaluated using broth dilution method in 96 
well plates. Enzyme inhibitory activities assays were investigated against α-glucosidase, 
butyrylcholinesterase (BchE) and lipoxygenase (LOX) using acarbose, eserine and baicalien as 
reference standards, respectively. A mixture of enzyme, test compound and the substrate was 
incubated and variation in absorbance noted before and after incubation. In tests for hemolytic activities, 
the compounds were incubated with red blood cells and variations in absorbance were used as indices 
their hemolytic activities. 
Results: The compounds were potent antibacterial agents. Five of them exhibited very good anti-
bacterial potential similar to ciprofloxacin, and had minimum inhibitory concentrations (MIC) of at least 
9.00 ± 4.12 µM against S. aureus, E.coli, and B. subtilis. One of the compounds had strong enzyme 
inhibitory potential against α-glucosidase, with IC50 of 17.11 ± 0.02 µg/mL which was better than that of 
standard acarbose (IC50 38.25 ± 0.12 µg/mL).  Another compound had 1.5 % hemolytic activity.  
Conclusion: S-Alkylated/aralkylated 2-(1H-indol-3-ylmethyl)-1,3,4-oxadiazole-5-thiol deviratives with 
valuable antibacterial, anti-enzymatic and hemolytic activities have been successfully synthesized. 
These compounds may be useful in the development of pharmaceutical products.  
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The synthesis and evaluation of 2, 5-
disubstituted-1,3,4-oxadiazole-2-thiol derivatives 
have received attention in the past decades. The 
medicinal values of these compounds are 
diverse, and include anti-edema and anti-
inflammatory, anti-microbial, analgesic, anti-
mycobacterial, anti-convulsant, anti-tumor, anti-
malarial,  anti-hepatitis B, anti-tuberculosis, 
insecticidal, anti-HIV and anti-Parkinsonism  
activities [1,2]. The ability of these compounds to 
Rubab et al 
Trop J Pharm Res, July 2016; 15(7): 1526  
 
inhibit certain enzymes such as cholinesterases, 
α-glucosidase and lipoxygenase can exploited 
for medicinal purposes.  Cholinesterases are 
present in cholinergic and non-cholinergic 
tissues, as well as plasma and other body fluids 
[3-5].  α-glucosidase are used as oral anti-
diabetic drugs for the management of type-2 
diabetes mellitus [6]. Lipoxygenase are important 
enzymes in the biosynthesis of leukotrienes used 
for the treatment of inflammation and allergic 
diseases [7,8]. 
 
In continuation of our ongoing research efforts in 
search for new anti-bacterial, hemolytic and anti-
enzymatic agents [9,10],  we report herein the 
pharmacological activities of S-
alkylated/aralkylated 2-[1H-indol-3-ylmethyl]-






Three Gram negative bacterial strains 
(Escherichia coli, Pseudomonas aeruginosa and 
Salmonella typhi) and two Gram positive bacteria 
strains (Bacillus subtillis and Staphylococcus 
aureus) were clinically isolated and stored in 
agar culture medium for antibacterial evaluation. 
The enzymes, α-glucosidase (α-D-glucoside 
glucohydrolase EC 3.2.1.20), 
butyrylcholinesterase (BChE, EC 3.1.1.8) and 
lipoxygenase (LOX, EC 1.13.11.12) were 
obtained from freshly heparinized human blood 
which was collected from volunteers. 
 
Lipoxygenase (LOX) assay  
 
Lipoxygenase activity was assayed according to 
standard methods [11-13]. The assay mixture 
(200 µL) contained 150 µL of sodium phosphate 
buffer (100 mM, pH 8.0), 10 µL of test compound 
and 15 µL of purified lipoxygenase. The mixture 
was pre-read at 234 nm and pre-incubated for 10 
minutes at 25 °C. The reaction was then initiated 
by addition of 25 µL of substrate solution. 
Change in absorbance was observed after 6 min 
at 234 nm. All reactions were done in triplicates. 
Positive and negative controls were included in 
the assay. Quercetin (0.5 mM well-1) was used 
as positive control. Inhibition (%) was calculated 
as in Eq 1.  
 
Inhibition (%) = {(C – T)/C}100 …………… (1)                                
 
where C (i.e., control) = total enzyme activity 
without inhibitor, and T (i.e., test sample) = 
activity in the presence of test compound.  
 
IC50 values (concentration that results in 50 % 
enzyme inhibition) of the derivatives were 
calculated using EZ–Fit Enzyme kinetics 
software (Perella Scientific Inc. Amherst, USA). 
 
α-Glucosidase inhibitory assay 
 
α-Glucosidase inhibitory activity was determined 
according to the method of Pierre [14]. The 
assay mixture (100 µL) contained 70 µL of 50 
mM phosphate buffered saline (pH 6.8); 10 µl 
(0.5 mM) of test compound and 10 µl (0.057 
units) enzyme. The contents were mixed, pre-
incubated for 10 min at 37 ºC and pre-read at 
400 nm. Then 10 µl of 0.5 mM substrate (p-
nitrophenyl glucopyranoside) was added to 
initiate the reaction.  Acarbose was used as 
positive control. After 30 min of incubation at 37 
ºC, absorbance was measured at 400 nm using 
Synergy HT microplate reader. All experiments 
were carried out in triplicate. Inhibition (%) was 
calculated as in Eq 2. 
 
Inhibition (%) = {(C – T)/C}100 ……………… (2)                               
 
where C (i.e., control) = total enzyme activity 
without inhibitor, and T (i.e., test sample) = 
activity in the presence of test compound. IC50 
values (concentration that causes 50 % inhibition 
of enzyme catalyzed reaction) of compounds 
were calculated using EZ-Fit Enzyme Kinetics 
Software (Perrella Scientific Inc. Amherst, USA). 
 
Butyrylcholinesterase (BChE) inhibitory 
assay  
 
BChE inhibition activity was estimated according 
to the method of Ellman et al [15]. The reaction 
mixture (10 µL) contained 60 µL of Na2HPO4 
buffer (50 mM, pH 7.7); 10 µL of test compound 
(0.5 mM well-1) and 10 µL of BchE (0.5 unit well-
1). After mixing, it was pre- read at 405 nm and 
then pre-incubated for 10 minutes at 37 ºC. The 
reaction was initiated by addition of 10 µL (0.5 
mM well-1) of butyrylthiocholine iodide 
(substrate), followed by 10 µL of DTNB (0.5 mM 
well-1). After 15 min of incubation at 37 ºC, 
absorbance was measured at 405 nm. All 
experiments were carried out with their 
respective controls in triplicate. Eserine (0.5 mM 
well-1) was used as positive control.  Inhibition 
(%) was calculated as in Eq 3. 
 
Inhibition (%) = {(C – T)/C}100 ……………… (3)                               
 
where C (i.e., control) = total enzyme activity 
without inhibitor, and T (i.e., test sample) = 
activity in the presence of test compound. IC50 
values (concentration at which there is 50 % 
enzyme inhibition) of compounds were calculated 
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using EZ–Fit Enzyme kinetics software (Perella 
Scientific Inc. Amherst, USA).  Results are 
expressed as mean of triplicate ± SEM). 




This was performed in sterile 96-wells micro 
plates under aseptic environments. The method 
is based on the principle that microbial cell 
number increases as the microbial growth 
proceeds in a log phase, which results in 
increased absorbance of the broth medium [16, 
17]. Three gram-negative (Escherichia coli, 
Pseudomonas aeruginosa and Salmonella typhi) 
and two gram-positive bacteria (Bacillus subtilis, 
Staphylococcus aureus) maintained on agar 
medium were tested against the compounds. 
Test samples in suitable solvents and dilutions 
were pipetted into wells (20 µg/well) along with 
180 µL of freshly maintained overnight bacterial 
culture, after suitable dilution with fresh nutrient 
broth and incubated at 37 oC for 16-24 h.  
Absorbance was measured at 540 nm using 
microplate reader, before and after incubation, 
and the difference was noted as an index of 
bacterial growth. The percent inhibition was 
calculated as in Eq 4. 
 
Inhibition (%) = {100(X – Y)}/X   ……………… (4)  
 
where X is the absorbance in control with 
bacterial culture  and Y is the absorbance of test 
sample. 
 
Hemolytic activity assay 
 
Hemolytic activities of the compounds were 
studied by the reported method [18,19]. Freshly 
obtained heparinized human blood (3 mL) was 
collected from volunteers after consent and 
counseling. The blood was centrifuged for 5 min 
at 1000 g and the plasma was discarded. The 
cells were then washed three times with 5 mL of 
chilled (4 oC) sterile isotonic phosphate-buffered 
saline (PBS, pH 7.4). The concentration of 
erythrocytes was maintained at 108 cells per mL 
for each assay.  Hundred μL of each compound 
was separately mixed with erythrocytes (108 
cells/mL), and incubated for 35 min at 37 oC, 
followed by agitation after 10 min.  Thereafter  
the samples were placed on ice for 5 min and 
then centrifuged for 5 min at 1000 x g. 
Supernatant samples (100 μL) were taken from 
each tube and diluted 10 times with chilled (4 oC) 
PBS. Triton X-100 (0.1 % v/v) was used as 
positive control, while phosphate buffered saline 
(PBS) was used as negative control. Absorbance 
was read at 576 nm using μQuant (Bioteck, 





To predict the bioactive conformations, various 
compounds (ligands) were docked into the 
binding pockets of the selected proteins 
(enzymes) by using the default parameters of 
MOE-Dock program. Prior to docking, the protein 
molecules of α-glucosidase, LOX and BChE 
were retrieved from Protein Data Bank having 
PDB ID codes of 3NO4 (Resolution: 2.02Å), 1IK3 
(Resolution: 2.0Å)  and 1POP (Resolution: 2.0Å) 
respectively. All the water molecules were 
removed from receptor proteins and 3D 
protonation was carried out by using the 
Protonate 3D Option. The energies of protein 
molecules were minimized by using the default 
parameters of MOE 2009-10 energy minimization 
algorithm (gradient: 0.05, Force Field: 
MMFF94X). Then all the ligands were docked 
into the binding pockets (selective 
residues/amino acids as shown in the docking 
images) of the above mentioned proteins using 
Triangular Matching docking method. Re-docking 
procedure was also applied to validate the 
docking protocol. Each complex was analyzed 
for the type of interactions; bond distances and 




All   the   measurements   were   carried   out   in 
triplicate and presented as mean ± SEM. 
Statistical analysis was performed using 




Enzyme inhibitory activity  
 
In vitro screening of the synthesized compounds 
against α-glucosidase, BChE and LOX revealed 
that these molecules exhibited variable inhibitory 
potential as shown by their IC50 values (Table-1). 
The compound 3-{[5-(pentylsulfanyl)-1,3,4-
oxadiazol-2-yl]methyl}-1H-indole (6g) showed 
inhibitory potential against α-glucosidase with 
IC50 value of 17.11 ± 0.02 µg/mL as against 




yl}methyl)-1H-indole (6s) and 3-({5-[(2-
methylbenzyl)sulfanyl]-1,3,4-oxadiazol-2-
yl}methyl)-1H-indole (6t) produced inhibition 
activities against α-glucosidase with IC50 values 
of 49.33 ± 0.07, 87.55 ± 0.74 and 98.81 ± 0.69 
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µg/mL respectively. Compounds 3-{[5-(iso-
propylsulfanyl)-1,3,4-oxadiazol-2-yl]methyl}-1H-
indole (6d), 3-{[5-(allylsulfanyl)-1,3,4-oxadiazol-2-
yl]methyl}-1H-indole (6i) and 3-({5-[(3-
phenylethyl)sulfanyl]-1,3,4-oxadiazol-2-
yl}methyl)-1H-indole (6l) showed no inhibitory 
activity against the enzyme. The compound 3-
({5-[(4-chlorobenzyl)sulfanyl]-1,3,4-oxadiazol-2-
yl}methyl)-1H-indole (6p) showed inhibitory 
potential against BChE with IC50 value of 31.0 ± 
0.73 µg/mL relative to the standard Eserine (IC50 
= 0.85 ± 0.01 µg/mL). Compounds 3-({5-[(2-
chlorobenzyl)sulfanyl]-1,3,4-oxadiazol-2-
yl}methyl)-1H-indole (6n) and 3-({5-[(4-
chlorobenzyl)sulfanyl]-1,3,4-oxadiazol-2-
yl}methyl)-1H-indole (6p) had IC50 values 31.4 ± 
1.03 and 48.7 ± 2.98 µg/mL against LOX, relative 
to  standard baicalein (IC50 = 22.4 ± 1.30 µg/mL). 
 
Antibacterial activity  
 
The synthesized compounds exhibited variable 




indole (6d) and 3-({5-[(4-fluorobenzyl)sulfanyl]-
1,3,4-oxadiazol-2-yl}methyl)-1H-indole (6s) 
produced antibacterial potential against S. typhi, 
with MIC values of 10.26 ± 1.08, 10.06 ± 1.66 
and 10.64 ± 2.08 µM respectively. Some 
compounds such as 3-{[5-(iso-propylsulfanyl)-
1,3,4-oxadiazol-2-yl]methyl}-1H-indole (6d), 3-
({5-[(4-bromobenzyl)sulfanyl]-1,3,4-oxadiazol-2-
yl}methyl)-1H-indole (6r) and 3-({5-[(4-
fluorobenzyl)sulfanyl]-1,3,4-oxadiazol-2-
yl}methyl)-1H-indole, showed inhibition against 
E. coli, (6s) with MIC values 9.75 ± 1.33, 9.26 ± 
2.76 and 9.12 ± 2.15 µM respectively, as against 
standard ciprofloxacin (MIC = 7.89±1.54 µM). 
The compound 3-{[5-(allylsulfanyl)-1,3,4-
oxadiazol-2-yl]methyl}-1H-indole (6i) had MIC 
value of 10.43 ± 2.29 µM against P. aeruginosa. 
Compounds 3-{[5-(butylsulfanyl)-1,3,4-oxadiazol-
2-yl]methyl}-1H-indole (6f) and 3-({5-[(4-
bromobenzyl)sulfanyl]-1,3,4-oxadiazol-2-
yl}methyl)-1H-indole (6r) showed inhibitory 
potential against B. subtilis with MIC values of 




yl]methyl}-1H-indole (6d) showed inhibition 
potential against S. aureus with MIC values 9.14 
± 2.67 and 9.00 ± 4.12 µM, which are 
comparable to that of ciprofloxacin (8.11±2.12 
µM) (Table 2). 
 
 
Table 1: Enzyme Inhibition activities of the S-alkylated/aralkylated 2-(1H-indol-3-ylmethyl)-1,3,4-oxadiazole-5-
thiol derivatives (6a-u) 
 
Code 







6a 294.1±1.15  262±1.38  - 
6b 165.2±1.84  140±1.56  - 
6c 135.6±0.34  65.0±0.45  - 
6d -  245±0.61  - 
6e 228.5±1.81  134 ±0.29  >500 
6f 117.3±1.01  146±0.57  >500 
6g 17.11±0.02  345±1.78  - 
6h 49.33±0.07  343±1.89  >500 
6i -  434±0.34  - 
6j >400  66.1±2.18  136±0.99 
6k 463.9±2.48  340±3.90  >500 
6l -  142±2.65  >500 
6m 98.25±0.75  324±1.45  218±1.23 
6n 474.2±1.83  231±2.90  31.4±1.03 
6o 443.9±1.25  52.0±2.45  >500 
6p 431.7±1.87  31.0±0.73  48.7±2.98 
6q 319.1±1.96  160±0.36  >500 
6r 266.8±1.95  134±0.98  >500 
6s 87.55±0.74  54.5±1.90  135±1.09 
6t 98.81±0.69  70.0±3.16  130±0.34 







Values are mean ± SEM. (n=3) 
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Table 2: Antibacterial activities (% inhibition) of S-alkylated/aralkylated 2-(1H-indol-3-ylmethyl)-1,3,4-oxadiazole-
5-thiols (6a-u) 
 
Inhibition (%) S. typhi (-) E. coli (-) P. aeruginosa (-) B. subtilis (+) S. aureus(+) 
6a 56.73±0.18 44.45±3.00 40.83±0.71 42.45±4.55 56.35±0.75 
6b 77.09±0.00 70.50±2.23 75.75±0.67 62.32±5.00 68.30±0.10 
6c 82.27±0.27 82.00±0.36 83.04±1.79 64.00±0.55 77.65±0.85 
6d 79.95±2.50 73.09±3.45 75.17±2.08 63.55±5.00 67.25±1.35 
6e 69.77±1.23 49.82±4.55 62.67±3.08 55.73±4.27 63.05±4.55 
6f 64.09±2.81 52.41±5.00 70.88±3.79 64.64±1.55 58.85±2.45 
6g 62.91±1.64 53.05±2.77 67.83±1.50 55.09±3.00 57.75±1.75 
6h 59.09±1.00 48.45±2.82 49.46±1.38 46.86±4.50 63.75±0.05 
6i 78.45±2.45 72.05±0.41 68.21±0.54 68.32±0.41 64.55±0.65 
6j 71.64±0.73 69.36±0.36 67.33±3.50 62.50±3.95 67.65±0.05 
6k 70.77±1.59 59.27±0.45 67.17±1.33 58.41±1.05 62.00±3.60 
6l 65.32±1.41 54.68±1.50 57.04±2.21 60.00±1.64 56.90±0.50 
6m 60.95±0.05 52.00±0.27 56.71±0.13 55.86±1.23 55.40±2.30 
6n 65.23±1.23 53.18±3.00 52.00±3.75 46.73±5.00 51.80±1.10 
6o 56.68±0.50 52.09±0.09 54.67±0.42 49.91±1.00 52.65±1.55 
6p 59.50±1.14 51.00±1.91 55.92±0.58 54.09±2.64 63.85±1.55 
6q 59.64±1.18 47.09±4.73 57.38±1.54 51.27±3.27 66.35±1.65 
6r 73.95±0.68 65.41±0.23 72.92±0.33 67.23±1.41 64.45±0.45 
6s 65.41±0.23 68.36±0.18 74.38±1.21 49.95±2.77 57.05±0.45 
6t 72.00±0.45 62.27±1.55 65.75±0.58 58.68±0.50 64.50±1.20 
6u 64.00±0.55 48.18±1.36 53.25±0.25 56.55±3.55 50.35±2.65 
Ciprofloxacin 91.90±3.00 92.56±0.05 91.00±2.13 91.45±0.45 90.80±1.90 
MIC (µM)    
6a 12.54±0.96 - - - 14.65±0.74 
6b 14.35±1.21 10.23±1.65 12.70±1.97 13.33±1.56 10.98±1.50 
6c 10.26±1.08 11.21±2.12 14.42±2.17 13.24±1.88 9.14±2.67 
6d 10.06±1.66 9.75±1.33 11.22±1.64 10.89±2.34 9.00±4.12 
6e 11.43±1.97 - 14.67±2.41 14.37±3.00 12.44±2.64 
6f 13.62±0.59 16.53±0.54 12.78±1.48 9.75±3.65 15.75±2.29 
6g 12.62±1.11 15.46±0.76 12.83±2.09 15.41±2.00 12.89±1.41 
6h 15.68±0.45 - - - 12.59±0.33 
6i 11.83±2.00 10.63±1.39 10.43±2.29 10.75±2.61 11.44±2.14 
6j 13.16±0.66 13.57±0.66 13.52±1.43 12.18±1.78 10.10±2.00 
6k 14.02±0.98 12.74±1.58 13.76±2.71 11.51±1.84 13.85±1.67 
6l 11.90±1.60 13.53±1.93 16.08±3.72 13.40±1.47 10.59±0.74 
6m 15.18±3.23 14.99±0.67 18.02±5.00 12.70±2.53 10.32±1.55 
6n 15.94±0.62 18.25±0.22 18.81±5.00 14.00±1.22 18.81±5.00 
6o 16.82±1.00 17.02±1.81 16.64±4.42 13.89±2.03 16.64±4.42 
6p 12.01±2.45 16.66±1.00 16.30±3.75 12.24±2.15 16.30±3.75 
6q 12.66±1.03 - 13.33±1.75 15.50±3.00 13.33±1.75 
6r 12.08±1.38 9.26±2.76 15.64±2.33 9.96±2.95 15.64±2.33 
6s 10.64±2.08 9.12±2.15 11.34±2.25 12.71±2.00 11.34±2.25 
6t 13.95±0.22 12.37±1.32 14.09±2.50 12.56±1.24 14.09±2.50 
6u 11.13±2.12 14.99±0.67 17.30±3.08 18.51±4.00 17.30±3.08 
Ciprofloxacin 8.04±0.15 7.89±1.54 8.54±1.76 7.29±2.67 8.11±2.12 
Minimum inhibitory concentration (MIC) was measured with suitable dilutions (5-30 µg/ well) and results were 




The lowest hemolytic activity was exhibited by 
the compound 6c (1.50 %) which was similar to 
the negative control (PBS). Compounds 6f (5.37 
%), 6m (6.88 %), 6e (6.94 %) and 6l (7.63 %) 
also exhibited low hemolytic activities. The 
highest hemolytic activity was produced by 
compound 6u (20.56 %) but this was lower than 





Molecular docking studies confirmed the anti-
enzymatic activities of all the compounds Figure-
1. 2D and 3D docked pictures of some more 
potent compounds are given here. 
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Table 3: Hemolytic activities of S-alkylated/aralkylated 2-(1H-indol-3yl-methyl)-1,3,4-oxadiazole-5-thiols (6a-u) 
 
Code % Hemolysis Compound % Hemolysis Compound % Hemolysis 
6a 11.13 6h 7.44 6o 7.19 
6b 18.94 6i 13.44 6p 9.75 
6c 1.50 6j 17.56 6q 10.81 
6d 14.00 6k 10.31 6r 10.94 
6e 6.94 6l 7.63 6s 9.38 
6f 5.37 6m 6.88 6t 11.50 
6g 10.25 6n 8.25 6u 20.56 
PBS 00.00 Triton-X 100.00   
 
  
6g: (a-1) 2D interacted image of α-Glucosidase with 
the docked ligand after docking 
6g: (a-2) 3D interacted image of α-Glucosidase with the 
docked ligand after docking 
 
 
6p: (b-1) 2D interacted image of BChE with the 
docked ligand after docking 
6p: (b-2) 3D interacted image of BChE with the docked 
ligand after docking 
 
 
6n: (c-1) 2D interacted image of LOX with the 
docked ligand after docking 
6n: (c-2) 3D interacted image of LOX with the docked 
ligand after docking 
 
Figure 1: Binding modes of some of the compounds against α- glucosidase, BChE and LOX 
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Compounds bearing oxadiazole moieties have 
been previously synthesized by our research 
group and their biological activities were shown 
to be related to structural modifications in the 
molecules [20, 21]. The synthesis of these 5-(1H-
indol-3yl-methyl)-1,3,4-oxadiazole-2-thiols (6a-u) 
in the present study is a part of our continued 
efforts to generate new molecules with  biological 
activities. Our results revealed that the 5-(1H-
indol-3yl-methyl)-1,3,4-oxadiazole-2-thiol 
derivatives (6a-6u) had variable inhibitory 
potencies  against α-glucosidase, BChE and 
LOX. As expected, the compounds with 
comparatively more inhibitory activities were 
those that fitted more closely into the active sites 
of the enzymes inhibited. Compound 3-{[5-
(pentylsulfanyl)-1,3,4-oxadiazol-2-yl]methyl}-1H-
indole (6g) showed  excellent inhibitory potential 
against α-glucosidase,  which was even better 
than the reference standard, acarbose. This 
molecule contains n-pentyl group substituted at 
the thiol position of the oxadiazole ring along with 
the indole moiety. These structural features 
probably conferred on the compound the best fit 
into the active site of the enzyme, which might be 
responsible for its high inhibitory potency against 
α-glucosidase.  Similarly compounds 3-{[5-
(heptylsulfanyl)-1,3,4-oxadiazol-2-yl]methyl}-1H-
indole (6h), 3-({5-[(4-fluorobenzyl) sulfanyl]-1,3,4-
oxadiazol-2-yl}methyl)-1H-indole (6s) and 3-({5-
[(2-methylbenzyl)sulfanyl] -1,3,4-oxadiazol-2-
yl}methyl)-1H-indole (6t) also yielded relatively  
high inhibition potential against the enzyme. 
These molecules contain n- heptyl, 4-florobenzyl 
and 2-methylbenzyl substituents respectively at 
the thiol positions, which might be responsible for 
their being able to fit into the active site of α-
glucosidase.  
 
All the synthesized derivatives exhibited 
moderate to weak inhibition against BChE, 
whereas, comparatively better inhibition potential 
was shown by the compound 3-({5[(4-
chlorobenzyl)sulfanyl]-1,3,4-oxadiazol-2-
yl}methyl)-1H-indole (6p) against this enzyme, 
when compared to the standard Eserine. 
Compound 6p has S-substituted 4-chlorobenzyl 
group which might have been responsible for its 
better fitting into the active site of BChE [22]. 
Compounds 3-({5-[(2-chlorobenzyl)sulfanyl]-
1,3,4-oxadiazol-2-yl}methyl)-1H-indole (6n) and 
3-({5-[(4-chlorobenzyl)sulfanyl]-1,3,4-oxadiazol-
2-yl}methyl)-1H-indole (6p) which possess  2-
chlorobenzyl and 4-chlorobenzyl substituents 
respectively, showed good inhibitory potential 
against LOX, relative to standard Baicalein [23]. 
 
All the synthesized compounds exhibited variable 
antibacterial potential. It has been reported 
earlier that slight modifications in structure may 
affect antibacterial potential [24]. In this study we 
made changes at the thiol position of the parent 
indole-containing oxadiazole molecule (4) by 
substituting different alkyl/aralkyl groups to 
evaluate their antibacterial profile [25]. For 
example, the compounds 3-{[5-(propylsulfanyl)-
1,3,4-oxadiazol-2-yl]methyl}-1H-indole (6c), 3-
{[5-(iso-propylsulfanyl)-1,3,4-oxadiazol-2-
yl]methyl}-1H-indole (6d) and 3-({5-[(4-
fluorobenzyl)sulfanyl]-1,3,4-oxadiazol-2-
yl}methyl)-1H-indole (6s) which contain n-propyl, 
iso-propyl and 4-flourobenzyl groups 
respectively, at the thiol positions, showed good  
antibacterial activities against S. typhi. 
 
The compound 3-{[5-(iso-propylsulfanyl)-1,3,4-
oxadiazol-2-yl]methyl}-1H-indole (6d) and 3-({5-
[(4-bromobenzyl)sulfanyl]-1,3,4-oxadiazol-2-
yl}methyl)-1H-indole (6r) also showed good 
activities against E. coli along with 3-({5-[(4-
fluorobenzyl)sulfanyl]-1,3,4-oxadiazol-2-
yl}methyl)-1H-indole (6s), and their MIC values 
were close to that of standard ciprofloxacin. 
However the antibacterial activities of the 
compounds against P. aeruginosa were 
comparatively lower. Indeed only the compound 
3-{[5-(allylsulfanyl)-1,3,4-oxadiazol-2-yl]methyl}-
1H-indole (6i) exhibited appreciable  activity 
against this strain. The allylic group attached at 
the thiol position of the parent molecule (4) might 
be responsible for this activity. Compounds 3-{[5-
(butylsulfanyl)-1,3,4-oxadiazol-2-yl]methyl}-1H-
indole (6f) and 3-({5-[(4-bromobenzyl)sulfanyl]-
1,3,4-oxadiazol-2-yl}methyl)-1H-indole (6r) 
showed very good antibacterial potential against 
B. subtilis, which were very close to that of the 
standard drug. This might be attributed to the S-
substituted n-butyl and 4-bromobenzyl groups in 
these compounds.  Furthermore, compounds 3-
{[5-(propylsulfanyl)-1,3,4-oxadiazol-2-yl]methyl}-
1H-indole (6c), 3-{[5-(iso-propylsulfanyl)-1,3,4-
oxadiazol-2-yl]methyl}-1H-indole (6d) also 
yielded very good inhibition potential against S. 
aureus comparable to ciprofloxacin.  
 
The compound 3-{[5-(pentylsulfanyl)-1,3,4-
oxadiazol-2-yl]methyl}-1H-indole (6g) which 
exhibited excellent inhibitory potential against α-
glucosidase (even better than reference 
standard) also exhibited comparatively lower  % 
hemolytic activity. This is a desirable 
characteristic. In addition, compound 3-{[5-
(propylsulfanyl)-1,3,4-oxadiazol-2-yl]methyl}-1H-
indole (6c) which produced excellent anti-
bacterial effect on S. aureus, had the lowest % 
hemolytic activity.  
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Other compounds that exhibited comparable 
antibacterial activity against S. aureus, such as 
3-{[5-(iso-propylsulfanyl)-1,3,4-oxadiazol-2-
yl]methyl}-1H-indole (6d) also showed low % 
hemolytic activity. The  compounds 3-{[5-
(butylsulfanyl)-1,3,4-oxadiazol-2-yl]methyl}-1H-
indole (6f), 3-({5-[(4-bromobenzyl)sulfanyl]-1,3,4-
oxadiazol-2-yl}methyl)-1H-indole (6r) showed 
least values of % hemolytic activity and good 
values of antibacterial activity against B. subtilis. 
The compound 3-({5-[(4-fluorobenzyl)sulfanyl]-
1,3,4-oxadiazol-2-yl}methyl)-1H-indole (6s), also 
exhibited comparatively lower values of % 
hemolytic activity and good antibacterial activity 
against both S. typhi and E. coli. 
 
On the basis of these results, it seems 
reasonable to assume that these synthesized 
thiol derivative compounds are either non-toxic or 
at most, only moderately so. Thus they may be 
suitable drug candidates for further 
investigations. 
 
In order to test the validity of our enzyme 
inhibition results, the co-crystallized ligands of 
the enzymes were extracted and then re-docked 
into the binding pockets of the receptors. In all 
cases, RMSD values between docked and co-
crystallized ligands were less than 2A° which 
indicated the reliability of docking method. Thus 
our protocol can be used for further studies. 
Almost all the synthesized derivatives were 
computationally docked against α-glucosidase, 
BChE and lipoxygenase to explore the binding 
modes of all the ligands.  
 
The results were very much in favor of the 
experimental data. For example, 3-{[5-
(pentylsulfanyl)-1,3,4-oxadiazol-2-yl]methyl}-1H-
indole (6g) showed interactions with two active 
site amino acid residues of the target protein. 
Amino acid Asp B307 showed a hydrogen bond 
acceptor (polar) interaction with –NH group of 
indole moiety with a bond distance of 2.10 
angstroms, while Trp307 showed arene-arene 
interaction with oxadiazole ring having a bond 
distance of 3.44 angstroms. The other residues 
present in the nearby vicinity of the ligand were 
Trp B269, Arg B404 and IleB198.   
 
Two amino acid residues interacted with 3-({5-
[(4-chlorobenzyl)sulfanyl]-1,3,4-oxadiazol-2-
yl}methyl)-1H-indole (6p). Tyr A332 showed two 
arene- arene interactions with indole moiety 
showing bond length of 3.39 angstroms with six 
membered ring of indole moiety on one hand, 
and 3.34 angstroms with five membered ring of 
indole moiety on the other hand. Other residues 
found in close contact with the ligand were Thr 
A120, and Asp A70. Two amino acid residues 
interacted with compound 3-({5-[(2-
chlorobenzyl)sulfanyl]-1,3,4-oxadiazol-2-
yl}methyl)-1H-indole (6n) as Trp A82 showing 
two arene-arene interactions with  five 
membered ring of indole moiety  having bond 
length of 3.46 angstroms  and  with other five 
membered ring of oxadiazole with bond length of 
3.25 angstroms. Tyr A332 showed arene-arene 
interaction with 2-chlorobenzyl ring having bond 
length of 3.94 angstroms. Other residues that 
existed in the near most region of the ligand were 




All the compounds exhibited variable anti-
enzymatic potential which were also supported 
by the molecular docking results. Compound 3-
{[5-(pentylsulfanyl)-1,3,4-oxadiazol-2-yl]methyl}-
1H-indole (6g)  showed excellent anti-enzymatic 
activity against α-glucosidase, which  was 
superior to that of the standard Baicalein. Their 
anti-bacterial activities revealed that the 
synthesized derivatives displayed moderate to 






oxadiazol-2-yl}methyl)-1H-indole (6r) and 3-({5-
[(4-fluorobenzyl)sulfanyl]-1,3,4-oxadiazol-2-
yl}methyl)-1H-indole (6s) showed MIC values 
very close to that of standard ciprofloxacin. 
These compounds also showed least to 
moderate % hemolytic activities. These results 
suggest that the 2-(1H-indol-3-ylmethyl)-1,3,4-
oxadiazole-5-thiol derivatives,  due to their 
multiple functional groups, possess remarkable 
anti-enzymatic and antibacterial potential with 
acceptable cytotoxicity levels. Thus they may be 
useful agents for development of new anti-
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